Clinical trials: Plaque Psoriasis.
Chronic Plaque Psoriasis
Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- FIXTURE (NCT01358578)
- Testing
- secukinumab (AIN457), etanercept
- Where
- 152 sites in United States, Argentina and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis
The main purpose of this study is to assess the effect of smoking status on the success of Etanercept therapy in patients with moderate-to-severe psoriasis.
- Trial name
- NCT02570750
- Testing
- QUESTIONNAIRE ON SMOKING HABITS
- Where
- 30 sites in Romania
- Volunteers
- 183 people
- Sponsor
- Pfizer
Moderate to Severe Plaque Psoriasis
Phase IV Study: Vunakizumab Efficacy and Safety in Moderate-to-severe Plaque Psoriasis
This is a prospective, single-arm, multicenter, Phase IV study of 1564 patients with moderate-to-severe chronic plaque psoriasis to evaluate the efficacy and safety of Vunakizumab in patients with moderate-to-severe plaque…
- Trial name
- NCT06779097
- Testing
- Vunakizumab (IL-17A inhibitor)
- Where
- China
- Volunteers
- 1,564 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Moderate to Severe Chronic Plaque Psoriasis
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate…
- Trial name
- STELLAR-2 (NCT05335356)
- Testing
- Stelara, Bmab1200
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Biocon Biologics UK Ltd
Plaque Psoriasis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03298581
- Testing
- Halobetasol Propionate
- Sponsor
- Sun Pharmaceutical Industries Limited
Psoriasis Vulgaris
An Exploratory Psoriasis Plaque Test Study With LEO 29102 Plus Calcipotriol, Ointment, in Psoriasis Vulgaris
The purpose of the study is to compare the 3 ointment formulations containing LEO 29102 plus calcipotriol and Daivonex® ointment and Diprosone® ointment and to compare LEO 29102 plus calcipotriol to LEO 29102 alone and to…
- Trial name
- NCT01466478
- Testing
- Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment, Ointment B: LEO 29102 2.5 mg/g ointment, Ointment C: Calcipotriol 50 µg/g ointment
- Where
- France
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis
Evaluate the efficacy of Clobex® Spray as compared to Taclonex® Ointment in terms of Overall Disease Severity and Investigator Global Assessment.
- Trial name
- NCT00437255
- Testing
- Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
- Where
- 4 sites in United States
- Volunteers
- 122 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis.
- Trial name
- NCT06088043
- Testing
- TAK-279, Apremilast
- Where
- 132 sites in United States, Australia and 8 more
- Volunteers
- 693 people
- Sponsor
- Takeda
Stable Plaque Psoriasis
A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis
This study is conducted to assess the efficacy and safety of LEO 90100 when used on the body for the treatment of stable plaque psoriasis in native adult Chinese subjects, compared to Daivobet® ointment.
- Trial name
- NCT05919082
- Testing
- LEO 90100, Daivobet® ointment
- Where
- 38 sites in China
- Volunteers
- 604 people
- Sponsor
- LEO Pharma
Psoriasis
Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the effect of guselkumab on coronary flow reserve (CFR), measured by transthoracic doppler-echocardiography, in participants with moderate-to-severe psoriasis and intermediate…
- Trial name
- G-CARE (NCT05125679)
- Testing
- Guselkumab
- Where
- 5 sites in Germany, Greece and 1 more
- Volunteers
- 15 people
- Sponsor
- Janssen-Cilag Ltd.
Plaque Psoriasis
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of 12 weeks of treatment with Apo805K1 in subjects with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01483924
- Testing
- Apo805K1
- Where
- 7 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- ApoPharma
Moderate to Severe Plaque-type Psoriasis
Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis
This study is designed to support the optimal use of secukinumab by providing data to refine guidance on dosing flexibility in patients with psoriasis.
- Trial name
- GAIN (NCT02474069)
- Testing
- Secukinumab
- Where
- 89 sites in Germany
- Volunteers
- 772 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Open Label Study to Evaluate the Safety and Efficacy of AK101 Injection Subcutaneously in Subjects With Psoriasis
This is an open-label Phase III clinical study to evaluate the long-term safety and efficacy of AK101 injection in subjects with moderate-to-severe plaque psoriasis.
- Trial name
- NCT05509361
- Testing
- AK101 injection SC
- Where
- China
- Volunteers
- 950 people
- Sponsor
- Akeso
Psoriasis
A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis
This study is a randomized, active-controlled, double-blind, phase 3 study to compare the efficacy and safety of CT-P43 to Stelara in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT04673786
- Testing
- CT-P43, Stelara
- Where
- Estonia
- Volunteers
- 509 people
- Sponsor
- Celltrion
Psoriasis
Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis.
- Trial name
- NCT03850483
- Testing
- PF-06700841
- Where
- 79 sites in United States, Australia and 8 more
- Volunteers
- 344 people
- Sponsor
- Pfizer
Plaque Psoriasis
A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to evaluate long-term clinical response of JNJ-77242113 treatment in participants with moderate-to-severe plaque psoriasis.
- Trial name
- FRONTIER 2 (NCT05364554)
- Testing
- JNJ-77242113
- Where
- 60 sites in United States, Canada and 8 more
- Volunteers
- 227 people
- Sponsor
- Janssen Research & Development, LLC
Plaque Psoriasis
A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis
This is a phase Ⅲ, randomized, double-blind, placebo-controlled, parallel design, multicenter trial to evaluate the efficacy, safety, tolerability, and immunogenicity of subcutaneous Tildrakizumab in subjects with moderate to…
- Trial name
- NCT05108766
- Testing
- Tildrakizumab 100 mg
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Psoriasis
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of Secukinumab in patients with moderate-severe chronic plaque psoriasis.
- Trial name
- NCT06398652
- Testing
- CMAB015, Secukinumab
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Chronic Plaque-type Psoriasis
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent to which the patient's body…
- Trial name
- NCT01071252
- Testing
- AIN457
- Where
- 19 sites in United States, Canada and 4 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis
Pharmacokinetic, Efficacy, Safety, and Immunogenicity Between Patients with Moderate to Severe Chronic Plaque Psoriasis Receiving Humira® and Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT04453137
- Testing
- Adalimumab originator, Adalimumab biosimilar
- Where
- 25 sites in Georgia, Iceland and 3 more
- Volunteers
- 567 people
- Sponsor
- Alvotech Swiss AG